Cargando…
P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430074/ http://dx.doi.org/10.1097/01.HS9.0000847576.88118.d6 |
| _version_ | 1784779647872925696 |
|---|---|
| author | Bartlett, N. L. Yasenchak, C. A. Ashraf, K. K. Harwin, W. N. Orcutt, J. Kuriakose, P. Zinzani, P. L. Mamidipalli, A. Fenton, K. Glenn, C. Nowakowski, G. |
| author_facet | Bartlett, N. L. Yasenchak, C. A. Ashraf, K. K. Harwin, W. N. Orcutt, J. Kuriakose, P. Zinzani, P. L. Mamidipalli, A. Fenton, K. Glenn, C. Nowakowski, G. |
| author_sort | Bartlett, N. L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430074 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94300742022-08-31 P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY Bartlett, N. L. Yasenchak, C. A. Ashraf, K. K. Harwin, W. N. Orcutt, J. Kuriakose, P. Zinzani, P. L. Mamidipalli, A. Fenton, K. Glenn, C. Nowakowski, G. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430074/ http://dx.doi.org/10.1097/01.HS9.0000847576.88118.d6 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Bartlett, N. L. Yasenchak, C. A. Ashraf, K. K. Harwin, W. N. Orcutt, J. Kuriakose, P. Zinzani, P. L. Mamidipalli, A. Fenton, K. Glenn, C. Nowakowski, G. P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_full | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_fullStr | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_full_unstemmed | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_short | P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY |
| title_sort | p1178: brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory dlbcl: safety and efficacy results from the safety run-in period of the phase 3 echelon-3 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430074/ http://dx.doi.org/10.1097/01.HS9.0000847576.88118.d6 |
| work_keys_str_mv | AT bartlettnl p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT yasenchakca p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT ashrafkk p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT harwinwn p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT orcuttj p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT kuriakosep p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT zinzanipl p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT mamidipallia p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT fentonk p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT glennc p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study AT nowakowskig p1178brentuximabvedotinincombinationwithlenalidomideandrituximabinpatientswithrelapsedrefractorydlbclsafetyandefficacyresultsfromthesafetyruninperiodofthephase3echelon3study |